News >

Expert Discusses Venetoclax Potential in MCL

Angelica Welch
Published: Friday, Jun 22, 2018

Toby Eyre, MBChB, MRCP

Toby Eyre, MBChB, MRCP

Venetoclax (Venclexta) monotherapy induced an overall response rate (ORR) of 60% in patients with poor-risk relapsed/refractory mantle cell lymphoma (MCL) previously treated with a BTK inhibitor. Of the responders, 20% had a complete response (CR), according to results presented at the 2018 European Hematology Association Congress.

Toby Eyre, MBChB, MRCP, lead author of the retrospective study, said that among recent advances in MCL, there remains an area of unmet need for those who relapse after receiving treatment with a BTK inhibitor. Overall survival (OS) for patients with relapsed/refractory MCL remains at 2 years, he added.

The UK Medicines and Healthcare Products Regulatory Agency compassionate use scheme was used in this study to identify 20 patients who had failed BTK inhibition therapy. These patients then received monotherapy with venetoclax, efficacy data of which had never been collected in the post-BTK inhibitor setting, investigators noted.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication